Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 10/20 | 0.49 |
| ▸ | LMNA | P02545 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 4/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.48 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 4/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 3/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31124457 | 0.91 | SMN1; SMN2 (0.51) | SMN1; SMN2LMNAMEN1KMT2AMAPT | |
| SCHEMBL28919354 | 0.85 | SMN1; SMN2 (0.51) | SMN1; SMN2LMNAMEN1KMT2AGRM4 | |
| SCHEMBL31124418 | 0.85 | SMN1; SMN2 (0.51) | SMN1; SMN2LMNAMEN1KMT2AGRM4 | |
| SCHEMBL30497704 | 0.82 | SMN1; SMN2 (0.58) | SMN1; SMN2LMNAMEN1KMT2AMAPT | |
| SCHEMBL4495244 | 0.82 | SMN1; SMN2 (0.58) | SMN1; SMN2LMNAMEN1KMT2AMAPT | |
| SCHEMBL29689724 | 0.81 | ACACB (0.46) | — | |
| SCHEMBL31124452 | 0.80 | JAK3 (0.54) | SMN1; SMN2LMNAMEN1KMT2AGRM4 | |
| SCHEMBL31124509 | 0.80 | JAK3 (0.54) | SMN1; SMN2LMNAMEN1KMT2AGRM4 | |
| SCHEMBL28605626 | 0.80 | JAK3 (0.54) | SMN1; SMN2LMNAMEN1KMT2AGRM4 | |
| SCHEMBL28605629 | 0.80 | JAK3 (0.54) | SMN1; SMN2LMNAMEN1KMT2AGRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12110287-B2 | Heterocyclic derivatives as Nav1.7 and Nav1.8 blockers | RAQUALIA PHARMA INC. (JP) | 2024-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12110287-B2 | Heterocyclic derivatives as Nav1.7 and Nav1.8 blockers | SCN8A, SCN7A, SCN1A | SMN1; SMN2 359/4885LMNA 803/4885MEN1 2843/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.